Search results for: Chronic Diseases
Filter search results
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…high cost of drugs for rare diseases (often known as orphan drugs) has generated considerable debate. Many health economists argue there is no justification for a premium for ‘rarity’; orphan…
Common Illness of Our Time: a Study of the Problem of Ischemic Heart Disease
1 July 1966
In England and Wales in 1963, 187,023 deaths were certified as due to diseases of the heart. These included 154,815 deaths due to arteriosclerotic and degenerative heart disease of which…
Analysing Global Immunisation Expenditure
15 April 2025
…vaccines to susceptible populations to prevent the spread of infectious diseases. Key takeaways On average, the countries in focus spend 0.08% of their GDP on immunisation, and less than 1%…
The cost of inaction on LDL cholesterol
24 June 2026
OHE research on the burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases estimated that atherosclerotic cardiovascular disease (ASCVD) could cost the world up to Int$1.4 trillion annually in direct and indirect costs….
New: Priority Review Vouchers and Innovation
17 February 2011
…development of drugs for neglected diseases, judged against accepted criteria Download Grabowksi, H.G. Priority Review Vouchers to encourage innovation for neglected diseases. Seminar Briefing. (8). London: Office of Health Economics….
Drugs and Vaccines for Developing Countries
1 June 2011
…policies and proposals intended to increase access to both ‘global’ and ‘neglected’ diseases, including pricing, compulsory licensing, donations and ‘push’ and ‘pull’ mechanisms to stimulate R&D. The world faces many…
Pneumonia in Decline
4 January 1963
…fallen so that microbes, formerly harmless, become harmful. Traditionally, diseases have been described by the effects they produce, as collections of symptoms, and changes in the tissues seen after death….
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
…infectious diseases, thereby increasing the probability of complications, morbidity and mortality. The World… Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
The high cost of drugs for rare diseases (‘orphan drugs’) has generated considerable debate. While there is debate in the economic literature over whether a premium should be paid for…